FDA import refusal: Tirzepatide (Anti-diabetic) (China)
FDA rejects tirzepatide shipment from China due to violations.
What changed & why it matters
Med Spa Radar recorded an FDA import refusal at the federal level, dated July 24, 2026, in the GLP-1 Compounding category, naming TIRZEPATIDE.
An import refusal marks a shipment of TIRZEPATIDE the FDA stopped at the U.S. border as violative — the gray-market corridor a med spa must never source injectables from. Foreign, unapproved, or misbranded product refused at import is exactly what surfaces when a practice buys outside verified US-licensed 503A/503B or FDA-registered channels.
- Type
- FDA Import Refusal
- Jurisdiction
- Federal
- Category
- GLP-1 Compounding
- Substance
- TIRZEPATIDE
- Recorded
- July 24, 2026
What this means for your specific practice — the exact step to take, the deadline to calendar, or the supplier detail to check — is in the member "what to do" below. This page is the free record of what changed and why it matters.
What to do
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get the full “what to do” on every alert — in real time, for your states. Become a member →
The FDA record
- Firm
- CHONGUHAN MEDICAL TECHNOLOGIES
- Origin
- Guangzhou, China
- Product
- Tirzepatide (Anti-Diabetic)
- FDA classification
- Human Drugs
- Refused
- Jul 24, 2026
- FDA district
- Division of Southeast Imports
- Firm FEI
- 3045200803
- FDA shipment ID
- AEK-0834622-2/10002/1
Why FDA refused it
Unapproved New Drug505(a), 801(a)(3); UNAPPROVED NEW DRUG
The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).
FDA charge codes on this record: 75 (Unapproved New Drug). Definitions via the FDA Refusal Charges Reference.
Verify at FDA
FDA doesn’t publish a page per refusal. Open the FDA Import Refusals database and search by shipment ID AEK-0834622-2/10002/1 (or firm FEI 3045200803), refused Jul 24, 2026.
FDA Import Refusal · FDA Import Refusals database ↗FDA record · CHONGUHAN MEDICAL TECHNOLOGIES · Guangzhou · drug product · refused as unapproved new drug
Related alerts
- FDA recall (Class II): Semaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe, Ks 66061,…
- FDA recall (Class II): Semaglutide, 2.5 mg/mL injection, 2 mL., Boothwyn Pharmacy
- FDA recall (Class II): Tirzepatide + Niacinamide 16.6 mg + 1.0mg/0.5 mL Inj Sol, Inject 0.5 mL (50 units on syringe) subcutaneously, Sterile, …
- FDA recall (Class II): Tirzepatide Injections, 30mg/mL, pre-filled syringe, Thrive Health Solutions, 88 Inverness, Cir E, Suite A-204, Englewo…
- FDA recall (Class II): Wegovy (Semaglutide) Injection, 0.5 mg/0.5 mL, 4 Single-Dose Prefilled Pens, Manufactured by: Novo Nordisk A/S, DK-2880…
- FDA recall (Class II): Wegovy (Semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous Use Only, Rx …
Monitoring, not legal advice.